Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | DUT | P33316 | 2/20 | 0.41 |
| ▸ | TK2 | O00142 | 8/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14578023 | 0.88 | KIF11 (0.55) | KIF11HRH4DUTTK2TSHR | |
| SCHEMBL5282316 | 0.87 | KIF11 (0.59) | KIF11HRH4DUTTK2TSHR | |
| SCHEMBL9215766 | 0.86 | KIF11 (0.49) | KIF11SLC6A1 | |
| SCHEMBL11275984 | 0.85 | KIF11 (0.74) | KIF11HRH4DUTTK2TSHR | |
| SCHEMBL9637348 | 0.84 | KIF11 (0.55) | KIF11HRH4DUTTK2TSHR | |
| SCHEMBL28093026 | 0.81 | KIF11 (0.56) | KIF11HRH4DUTTK2TSHR | |
| SCHEMBL9215761 | 0.79 | KIF11 (0.42) | KIF11SLC6A1ALDH1A1 | |
| SCHEMBL31430932 | 0.79 | KIF11 (0.65) | KIF11HRH4DUTTK2TSHR | |
| SCHEMBL2348691 | 0.79 | KIF11 (0.65) | KIF11HRH4DUTTK2TSHR | |
| Phosphine SCHEMBL8595812 | 0.79 | KIF11 (0.54) | KIF11HRH4DUTTK2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807827-B2 | Procedure for preparing 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazineyl)-dibenzo[b,f] [1,4]thiazepine | INKE, S.A. (ES) | 2010-10-05 | — | — | US | disclosed |
| EP-1660468-B1 | PROCEDURE FOR PREPARING 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL)-DIBENZO[B,F][1,4]THIAZEPINE | INKE SA (ES) | 2007-07-18 | — | — | EP | disclosed |
| US-20060189594-A1 | Procedure for preparing a pharmaceutically active compound | INKE, S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
| EP-1660468-A2 | PROCEDURE FOR PREPARING 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL)-DIBENZO[B,F][1,4]THIAZEPINE | INKE, S.A. (ES) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005014590-A2 | PROCEDURE FOR PREPARING 11-(4`2-(2-HYDROXYETHOXY )ETHYL!-1-PIPERAZINYL!-DIBENZO`B,F!`1,4!THIAZEPINE | INKE, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189594-A1 | Procedure for preparing a pharmaceutically active compound | CYP3A5, CYP2C19, CYP3A7 | KIF11 3148/4885HRH4 3158/4885DUT 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.